Richard Arndt

Richard Arndt

Auto-generated profile, based on publicly available information

Richard Arndt

Department of Pharmacy, Mayo Clinic Health System, Eau Claire, WI

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in eClinicalMedicine
Verified
Journal Article
Open access
RRRaymund R. Razonable
Raymund R. Razonable
CPColin Pawlowski
Colin Pawlowski
JOJohn C. O'HOro
John C. O'HOro
LALori L. Arndt
Lori L. Arndt
RARichard Arndt
Richard Arndt
RGRavindra Ganesh
Ravindra Ganesh
Real-world clinical data to support the use of casirivimab–imdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimab–imdevimab treatment of mild to moderate COVID-19. A retrospective cohort of 696 patients who received casirivimab–imdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion. The median age of the antibody-treated cohort was 63 years (interquartile range, 52–71); 45·5% were ≥65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index ≥35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensity-matched untreated control, patients who received casirivimab–imdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference: 2.0%; 95% confidence interval (CI): 0.5–3.7%), day 21 (1.3% vs 4.2%; Absolute Difference: 2.9%; 95% CI: 1.2–4.7%), and day 28 (1.6% vs 4.8%; Absolute Difference: 3.2%; 95% CI: 1.4–5.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups. Among high-risk patients with mild to moderate COVID-19, casirivimab–imdevimab treatment was associated with a significantly lower rate of hospitalization. Mayo Clinic.

1 October 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RGRavindra Ganesh
Ravindra Ganesh
CPColin Pawlowski
Colin Pawlowski
JOJohn C. O’hOro
John C. O’hOro
LALori L. Arndt
Lori L. Arndt
RARichard F. Arndt
Richard F. Arndt
RRRaymund R. Razonable
Raymund R. Razonable
BACKGROUND. Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) are needed. METHODS. 2335 Patients who received single-dose bamlanivimab infusion between November 12, 2020, and February 17, 2021, were compared with a propensity-matched control of 2335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21, and 28. RESULTS. The median age of the population was 63 years; 47.3% of the bamlanivimab-treated cohort were 65 years or more; 49.3% were female and 50.7% were male. High-risk characteristics included hypertension (54.2%), BMI greater than or equal to 35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs. 3.5%; risk ratio [RR], 0.41), 21 (1.9% vs. 3.9%; RR, 0.49), and 28 (2.5% vs. 3.9%; RR, 0.63). Secondary exploratory outcomes included lower intensive care unit (ICU) admission rates at days 14 (0.14% vs. 1%; RR, 0.14), 21 (0.25% vs.1%; RR, 0.25), and 28 (0.56% vs.1.1%; RR. 0.51) and lower all-cause mortality at days 14 (0% vs. 0.33%), 21 (0.05% vs. 0.4%; RR,0.13), and 28 (0.11% vs. 0.44%; RR, 0.26). Adverse events were uncommon with bamlanivimab, occurring in 19 of 2355 patients, and were most commonly fever (n = 6), nausea (n = 5), and lightheadedness (n = 3). CONCLUSIONS. Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization, ICU admission, and mortality compared with usual care. FUNDING. Mayo Clinic.

16 December 2021 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
JOJohn C. O’hOro
John C. O’hOro
DCDouglas W. Challener
Douglas W. Challener
LSLeigh Speicher
Leigh Speicher
WBWendelyn Bosch
Wendelyn Bosch
MSMaria Teresa Seville
Maria Teresa Seville
RRRaymund R. Razonable
Raymund R. Razonable

23 February 2022 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
JOJohn O’hOro
John O’hOro
DCDouglas W. Challener
Douglas W. Challener
RARyan J. Anderson
Ryan J. Anderson
RARichard F. Arndt
Richard F. Arndt
SASara E. Ausman
Sara E. Ausman
RRRaymund R. Razonable
Raymund R. Razonable

11 January 2023 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
PJPatrick W. Johnson
Patrick W. Johnson
KKKatie L Kunze
Katie L Kunze
JSJonathon W. Senefeld
Jonathon W. Senefeld
JSJorge E. Sinclair
Jorge E. Sinclair
SIShahin Isha
Shahin Isha
LSLeigh L. Speicher
Leigh L. Speicher
To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently better in identifying the need for monoclonal antibody infusion throughout each "wave" of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant predominance during the coronavirus disease 2019 (COVID-19) pandemic and that the infusion of contemporary monoclonal antibody treatments is associated with a lower risk of hospitalization. In this retrospective cohort study, we evaluated the efficacy of monoclonal antibody treatment compared with that of no monoclonal antibody treatment in symptomatic adults who tested positive for SARS-CoV-2 regardless of their risk factors for disease progression or vaccination status during different periods of SARS-CoV-2 variant predominance. The primary outcome was hospitalization within 28 days after COVID-19 diagnosis. The study was conducted on patients with a diagnosis of COVID-19 from November 19, 2020, through May 12, 2022. Of the included 118,936 eligible patients, hospitalization within 28 days of COVID-19 diagnosis occurred in 2.52% (456/18,090) of patients who received monoclonal antibody treatment and 6.98% (7,037/100,846) of patients who did not. Treatment with monoclonal antibody therapies was associated with a lower risk of hospitalization when using stratified data analytics, propensity scoring, and regression and machine learning models with and without adjustments for putative confounding variables, such as advanced age and coexisting medical conditions (eg, relative risk, 0.15; 95% CI, 0.14-0.17). Among patients with mild to moderate COVID-19, including those who have been vaccinated, monoclonal antibody treatment was associated with a lower risk of hospital admission during each wave of the COVID-19 pandemic.

9 January 2025 in The American Journal of Surgery
Verified
Journal Article
Closed access
WCWill Carns
Will Carns
RARichard Arndt
Richard Arndt
SASara Ausman
Sara Ausman
JBJason Beckermann
Jason Beckermann
KCKristin C. Cole
Kristin C. Cole
BPBenjamin Pierce
Benjamin Pierce